Comparative Pharmacology
Head-to-head clinical analysis: METHYLTESTOSTERONE versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLTESTOSTERONE versus TREST.
METHYLTESTOSTERONE vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category D/X
Category C
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."